Treats dementia of the Alzheimer’s type. ANDA 204293, held by Sun Pharm. Donepezil Hydrochloride.
As of Nov 16, 2026, ANDA 204293 (Donepezil Hydrochloride), held by Sun Pharm, was first approved by FDA on Jun 5, 2015, with 1 approved supplement and 0 published complete response letters.
Donepezil hydrochloride tablets are indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 5, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Donepezil Hydrochloride23MG · tablet;oral | Donepezil Hydrochloride | Discontinued |
| Oct 4, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 5, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters